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ABSTRACT
Solid tumors grow at a high speed leading to insufficient blood supply to tumor 
cells. This makes the tumor hypoxic, resulting in the Warburg effect and an increased 
generation of reactive oxygen species (ROS). Hypoxia and ROS affect immune cells 
in the tumor micro-environment, thereby affecting their immune function. Here, 
we review the known effects of hypoxia and ROS on the function and physiology 
of dendritic cells (DCs). DCs can (cross-)present tumor antigen to activate naive 
T cells, which play a pivotal role in anti-tumor immunity. ROS might enter DCs via 
aquaporins in the plasma membrane, diffusion across the plasma membrane or via 
extracellular vesicles (EVs) released by tumor cells. Hypoxia and ROS exert complex 
effects on DCs, and can both inhibit and activate maturation of immature DCs. 
Furthermore, ROS transferred by EVs and/or produced by the DC can both promote 
antigen (cross-)presentation through phagosomal alkalinization, which preserves 
antigens by inhibiting proteases, and by direct oxidative modification of proteases. 
Hypoxia leads to a more migratory and inflammatory DC phenotype. Lastly, hypoxia 
alters DCs to shift the T- cell response towards a tumor suppressive Th17 phenotype. 
From numerous studies, the concept is emerging that hypoxia and ROS are mutually 
dependent effectors on DC function in the tumor micro-environment. Understanding 
their precise roles and interplay is important given that an adaptive immune response 
is required to clear tumor cells.
INTRODUCTION
When solid tumors grow, the oxygen demand 
increases rapidly while there is insufficient vascularization. 
This causes the tumor to become hypoxic at the tumor 
core and the edges of the invasive front [1]. Due to the 
lack of oxygen, ATP is mostly produced via a high rate 
of anaerobic glycolysis; this is called the Warburg effect. 
The Warburg effect leads to lactic acid fermentation in 
the cytosol and increased oxidative stress in the form of 
H2O2 and other radicals. H2O2 activates the transcription 
factor Nrf2 which further upregulates glycolysis-related 
genes and further contributes to the Warburg effect [2, 3]. 
ROS is important for tumor growth via the kinase AMPK. 
AMPK can suppress cell proliferation via cell cycle arrest 
[4] and its activation depends on reduction of cysteine 
residues by thioredoxin (Trx) at the catalytic subunit alpha 
[5, 6]. However, these sites can be oxidized by ROS to 
inactivate AMPK, promoting tumor cell proliferation. The 
increase in oxidative stress also translates to the tumor 
microenvironment (TME). The TME comprises the tumor 
cells itself and the stromal cell compartment directly 
surrounding it, containing blood vessels, cells from the 
immune system, fibroblasts and extracellular matrix [7, 8].
In cancer cells, there are multiple sources of ROS 
(Figure 1). Oncogenic mutations (e.g., in Ras, Myc and 
p53) can cause mitochondrial dysfunction and increased 
leakage of ROS. This leakage occurs mostly at complex 
1 or complex 3 of the respiratory chain, where electrons 
from NAD(P)H or FADH2 react with oxygen to form 
superoxide anion. Second, ROS is formed enzymatically 
by NAD(P)H oxidases (NOX), which can be activated by 
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various growth factors, such as VEGF and angiopoietin 
which are often upregulated in cancer [9, 10]. Third, 
exogenous radiation (e.g., UV light, radiotherapy) 
can cause the production of ROS [11]. Fourth, ROS 
are by-products of cellular metabolism such as from 
protein folding and beta-oxidation of fatty acids in the 
mitochondria and peroxisomes [2, 12]. Last, intracellular 
enzymes, such as xanthine oxidase, cyclooxygenases, 
cytochrome p450 enzymes, lipoxygenases and nitric 
oxide synthetase, generate ROS as a metabolic 
byproduct [11, 13]. Tumor cells thus have to cope with 
comparatively high intracellular levels of ROS and 
they do this by upregulating antioxidative systems 
such as Trx, peroxiredoxin (Prx), catalase, superoxide 
dismutases (SOD) and generation of NAD(P)H [13]. 
Against superoxide anion specifically, dismutation to 
H2O2 is the primary protective mechanism and this can 
occur enzymatically by SOD or spontaneously in acidic 
environments. Subsequently, H2O2 can then be degraded 
into water and oxygen by catalase [14].
In addition to cancer cells, ROS-producing immune 
cells of myeloid origin are present in the TME [15]. These 
include DCs (see below), but are mainly macrophages 
that have differentiated from circulating monocytes [16] 
and, depending on the stimulus, can develop towards 
more cytotoxic or immunosuppressive phenotypes [17]. 
However, tumor-associated macrophages in the TME are 
usually immunosuppressive, as they produce IL-10 and 
transforming growth factor β [18] and recruit regulatory T 
cells via CCL22 [19]. ROS produced by these cells were 
found to be detrimental for cancer progression, as increased 
H2O2 secretion by macrophages was shown to be a 
sufficient trigger for both tumor initiation and development 
of epithelial cancer [20]. This was further exacerbated by 
H2O2-mediated induction of TNF-α and TNF receptor 1 
transcription, which lead to recruitment of more H2O2-
secreting macrophages. Additionally, ROS production by 
the monocyte precursors of these macrophages was shown 
to be a strong determinant for development towards an 
immunosuppressive phenotype [21]. 
Hypoxia and oxidative stress influence multiple 
functions of the cancer cells, such as angiogenesis, cell 
proliferation and apoptosis, and thereby can promote 
tumorigenesis. H2O2 promotes angiogenesis by activating 
the transcription factors NF-κB and AP-1, leading 
to  activation of VEGF transcription factors NF-κB 
and AP1 [22], VEGF secretion [23] as well as VEGF 
receptor 2 transcription [24]. In addition, H2O2 can 
also activate VEGF receptor 2 in a ligand-independent 
manner via Src kinases [25]. VEGF activates NOX and 
thereby leads to the generation of more ROS, forming 
a positive feedback loop, and making NOX a potential 
therapeutic target for inhibition of angiogenesis [2, 9]. 
A major mechanism by which ROS affects physiological 
processes is by the formation of disulfide bonds. 
For example, H2O2 modifies the thiolates of cysteine 
residues in redox sensitive proteins [13] and particularly 
zinc-bound cysteines perform oxidative stress sensing 
[26]. Zinc-bound cysteines are present in zinc finger 
transcription factors, for example the GATA family of 
transcription factors and Krüppel-like Factor 2, both of 
which are involved in ROS-mediated signaling pathways 
[27–30]. Lastly, ROS influence apoptosis induced by the 
dimerization of the kinase ASK1 with TRAF2, which 
Figure 1: Targets and sources of ROS in DCs. (Left) ROS can attack both mono- and poly-unsaturated lipids in membranes, causing 
endosomal leakage and loss of pH and electron gradients. Cysteine residues on proteins can oxidize, resulting in the formation of disulfide 
bridges or a stepwise oxidation to sulfonic acid. This can activate redox-sensitive signaling factors, but also block enzymatic activity or 
cause protein misfolding. Finally, both free and DNA-helix incorporated guanine nucleotides can oxidize, leading to GC-TA or GC-CG 
transversion mutations. (Right) Sources of ROS for DCs in the TME: increased NOX (NAD(P)H oxidase) activity, ER stress due to the 
unfolded protein response, β-oxidation of fatty acids, abrogated electron transfer in mitochondria and uptake of ROS-containing tumor-
derived EVs.
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causes apoptosis via activation of the kinases JNK and 
p38 MAPK. This dimerization is induced by H2O2, but 
blocked by thioredoxin (Trx) [31, 32]. Trx is bound to 
ASK1 by a disulfide bond at the N-terminal domain 
of ASK1, leading to ubiquitination and proteosomal 
degradation of ASK1. High levels of H2O2 counteract 
the functioning of Trx and cause the release of Trx from 
ASK1, because of the formation of an intramolecular 
disulfide bond [33].
It is not completely understood how hypoxia and 
ROS in the TME influence infiltrating immune cells, 
which is the focus of this review. Especially DCs play 
a major role in generating anti-tumor immunity, due to 
their ability to activate naive T cells. After encountering 
an antigen, DCs can maturate and migrate to the lymph 
nodes to present processed antigens to T cells. The ability 
of DCs to (cross-)present antigens and activate T cells 
is influenced by the inflammatory environments that 
the cells encounter [34]. Since DCs encounter a variety 
of environments that differ in oxygen tension and ROS 
levels during antigen uptake and migration to the lymph 
nodes, it is likely that these environments affect the final 
immune response. The aim of this review is to provide a 
comprehensive overview of the effects of TME-associated 
oxidative stress on DCs.
ROS entry in DCs
Solid tumors are frequently invaded by DCs and 
other immune cells, which hence are exposed to the 
hypoxia and radicals in the TME. ROS may affect the 
plasma membrane composition of invading immune 
cells through oxidation of both the lipid bilayer and of 
membrane proteins [35]. However, to affect intracellular 
processes, ROS have to traverse the plasma membrane. 
Many species of ROS, such as superoxide anion, carry 
a free electron and cannot efficiently traverse the 
apolar lipid bilayers. However, either spontaneously or 
catalyzed by the abundant SODs, superoxide anion can 
dismutate to H2O2 which is uncharged and does not carry 
a free electron. H2O2 has a lower reactivity compared 
to ROS species such as superoxide anion and hydroxyl 
radicals and this makes H2O2 relatively stable and also 
allows it to diffuse through membranes and to enter the 
nucleus to cause DNA damage [11]. Its relatively high 
stability even allows H2O2 to signal between different 
cells [13]. These properties allow H2O2 to increase the 
redox potential of the TME. H2O2 cannot only passively 
diffuse through lipid membranes, but also enter cells 
through the aquaporin channel AQP8, as shown by 
heterologous expression in yeast [36], and through 
AQP1, 3 and 8 in a human leukemia cell line [37]. Both 
immature and monocyte-derived dendritic cells express 
AQP3, 7 and 9 and mature DCs express AQP7 and 9 
[38, 39], suggesting that H2O2 can enter DCs via these 
channels. Other aquaporins might be involved as well, 
as the homologs AQP7, AQP9, AQP10, AQP12A and 
AQP12B are all expressed by human immune cells [40]. 
Superoxide anion can enter endothelial cells by diffusion 
through the Cl- channel-3 (Clc3) [41] and might also enter 
immune cells via this channel, as it is expressed in human 
macrophages and peripheral blood mononuclear cells 
[42, 43]. However, there is no experimental evidence yet 
that these channels mediate entry of H2O2 and superoxide 
anion in DCs.
ROS affect DC maturation
ROS are directly implicated in DC maturation by 
the activation of p38-MAPK and ERK1/2. DCs treated 
with 1-fluoro-2,4-dinitrobenzene, a skin sensitizer which 
is perceived as a danger signal by DCs, showed increased 
ROS production and activation of p38-MAPK via an 
unknown mechanism [44]. In line with ROS promoting 
DC activation, H2O2-treated human peripheral blood DCs 
were more efficient in promoting T cell proliferation and 
showed an upregulation of cell surface molecules MHC-
II, CD40 and CD86, all important components of T cell 
activation [45]. The mechanism by which ROS promote 
DC maturation is not known.
ROS can also reduce DC maturation via ER stress. 
Danger signals such as 1-fluoro-2,4-dinitrobenzene 
cause accumulation of misfolded proteins in the cell, 
leading to ER stress and an increase in mitochondrial 
ROS production [44]. Oxidative stress can also affect 
ER function by disturbing Ca2+ homeostasis [44]. The 
accumulation of misfolded proteins activates the unfolded 
protein response, aimed at restoring normal cell function 
by halting translation, degradation of misfolded proteins, 
and increasing expression of chaperone proteins. This 
study observed that ROS affected the PERK-eIF2α-ATF4 
axis of the unfolded protein response, which led to a short-
term block of CD86, IL-1β and IL-12B expression in THP-
1 monocytes. However, these genes were upregulated 
at later time points, indicating a pro-inflammatory 
response. ER stress is also caused by lipid peroxidation 
products that follow increased ROS production, such 
as 4-hydroxynonenal (4-HNE). This aldehyde readily 
forms protein adducts due to its reactivity with thiols 
and amine groups [46], which can trigger the unfolded 
protein response. Additionally, 4-HNE was shown to 
form adducts with ER-resident chaperone proteins [47], 
leading to increased activation of ER stress transcription 
factor XBP1 in ovarian cancer-associated DCs [48]. This 
in turn inhibited anti-tumor immunity via accumulation 
of lipid bodies in the DC, which blocks translocation of 
MHC-I to the cell surface [48, 49]. As 4-HNE is relatively 
stable and able to diffuse through membranes, DCs may 
even internalize 4-HNE from the TME [50, 51]. Likewise, 
malondialdehyde, another common lipid peroxidation 
product, also forms protein adducts which are shown to be 
strongly auto-immunogenic, which may hamper specific 
anti-tumor responses [52–54]. 
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Effects of ROS on antigen presentation
ROS influence the ability of DCs to cross-present 
antigens to CD8+ cells [55]. Upon activation of Toll-like 
receptors (TLRs), NOX2 is activated in the DCs and produces 
large amounts of superoxide anion in endo/phagosomes 
[56–58]. This increases the endo/phagosomal pH through 
the consumption of protons by the dismutation of superoxide 
anion to H2O2 [55, 56]. The increased pH impacts cross-
presentation through antigen conservation, as lysosomal 
hydrolases with acidic pH optima are less activated [55]. 
In addition, ROS can affect the activity of the endosomal 
V-ATPase by formation of a disulphide bond between 
cysteine residues located within the nucleotide-binding 
subunits, leading to its inactivation and reduced acidification 
of the endosomal lumen [56, 59]. Endo/phagosomal proteases 
like cathepsins are modified in a similar fashion, leading to 
altered epitopes for both MHC-I and MHC-II [60–62]. ROS 
can also induce the release of antigen from phagosomes into 
the cytosol by causing leakage of antigens through lipid 
peroxidation of the endo/phagosomal membranes, and this 
can promote antigen cross-presentation [57, 63]. 
However, the effect on antigen presentation depends 
on the cellular site of ROS production, as a study in aged 
mice suggested an inhibitory role for mitochondrial 
ROS in cross-presentation by bone marrow-derived DCs 
[64]. DCs from aged mice (16–20 months) show signs 
of mitochondrial dysfunction, leading to increased ROS 
production compared to DCs from young mice (2–3 
months). Scavenging ROS partially improved the cross-
presentation efficiency of the DCs from aged mice [64]. 
This finding indicates that, although DCs actively use 
endo/phagosomal ROS to enable cross-presentation, a 
general increase in the environmental redox potential 
could also hamper cross-presentation.
Extracellular vesicle release by tumor cells
A recently identified source of ROS in the TME 
are EVs released by tumor cells. EVs  contain many 
different compounds, including ROS as shown by flow 
cytometry with a fluorescent ROS probe [58]. ROS was 
also found in EVs derived from hypoxic/reoxygenated 
human umbilical vein endothelial cells [65]. However, 
the source of EVs in the TME is still controversial, and 
it is debated whether cancer cells can dictate their content 
or they are only membrane blebs or necrotic cell bodies 
[66]. There is some evidence for controlled release of EVs 
in a process involving the endosomal sorting complex 
[67]. This complex generates the intraluminal vesicles of 
multivesicular bodies by bulging the membrane inwards 
onto the lumen of late endosomes. When multivesicular 
bodies fuse with the plasma membrane, these intraluminal 
vesicles are released as EVs [68, 69]. However, other 
mechanisms of EV formation have also been proposed, 
such as direct shedding from the plasma membrane 
[70, 71]. EVs of intracellular origin are often called 
exosomes, while EVs shed from the plasma membrane are 
called microvesicles. However, this nomenclature and the 
methods to discriminate between various sources of EVs 
are not yet standardized, therefore we will use the general 
term EVs in this review [66].
Several studies showed that hypoxia increases the 
release of EVs by various types of tumor cells, thereby 
suppressing the immune response [72, 73]. In a study 
on breast cancer cells, it was found that the transcription 
factor HIF-1α is responsible for this increase in EV 
production, since the release of EVs was blocked upon 
silencing of HIF-1α [73]. A second study on breast cancer 
cells came to a similar conclusion, and found that cells 
exposed to hypoxia overexpressed the small GTPase 
RAB22A in a HIF dependent manner, leading to increased 
formation of EVs in breast cancer [74]. The cargo of EVs 
is possibly influenced by hypoxia as well, as the level of 
the micro-RNA miR-210 is elevated in EVs upon hypoxia 
[73]. Transcription of miR-210 is mediated by HIFs and 
it has target genes involved in cell survival, angiogenesis 
and metabolism [75]. 
Effects of extracellular vesicles on DCs
EVs influence immune cells and for instance 
may control macrophage differentiation towards an 
immunosuppressive phenotype [76], but also might exert 
effects on DC function. Multiple mechanisms are suggested 
for the uptake of EVs by recipient cells: fusion, receptor-
ligand interactions and endocytosis. The uptake of EVs 
by DCs is mediated by several factors, including CD11a, 
intracellular adhesion molecule 1, phosphatidylserine 
and milk fat globule E8 on DCs, and tetraspanins CD9 
and CD81 on EVs [77]. Glycosylation is also involved 
in targeting EVs, as uptake of EVs derived from Jurkat T 
cells by myeloid DCs was inhibited by blocking Siglec-1 
[78]. Siglec-1 preferentially binds to α2,3-linked sialic 
acids which decorate proteins on the surface of EVs. 
Furthermore, EV uptake by DCs involves interaction 
between LFA-1 and C-type lectin receptors like DEC205 on 
DCs with CD54 or various glycoproteins on the EVs [79]. 
After uptake, the ROS present in EVs might affect 
DC function. EVs derived from ovarian cancer cells 
promote antigen cross-presentation in DCs via ROS-
mediated phagosomal alkalization [58], although in this 
study the effects of other EV components cannot be 
completely excluded. Moreover, it is unclear whether 
EV-derived ROS are directly responsible for ROS 
accumulation inside the phagosomes, or whether this is 
the result of ROS producing enzymes carried by the EVs 
[80] or other ROS-inducing components [81]. Besides 
changing the phagosomal pH, it is proposed that EVs 
induce antigen-specific tolerance in DCs. Tumor EVs 
contain antigens and EVs taken up by immature DCs 
are shown to inhibit the maturation of DCs [82]. In this 
study, EVs were internalized by mouse CD11c+ cells, 
which subsequently downregulated expression of the 
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maturation markers MHC-II and CD86, while levels of 
the anti-inflammatory cytokine transforming growth factor 
β1 were elevated in these DCs. This steered CD4+ T cells 
towards a regulatory phenotype, capable of suppressing B 
cell responses. The uptake of EVs by DCs can however 
also promote CD8+ T cell responses, benefitting antitumor 
immunity, because mature DCs pulsed with EVs expressed 
MHC-I, MHC-II, CD40, CD54 and CD80 at higher levels 
than controls, while immature DCs pulsed with EVs did 
not respond [79]. In fact, mice bearing BL6-10OVA tumor 
cells were able to clear their tumors following adoptive 
transfer with mature DCs pulsed with OVA-containing 
EVs, while DCs pulsed with soluble OVA only reduced 
tumor growth temporarily [79]. These EVs might 
potentially contain ROS and tumor material which induces 
ROS and danger-associated molecular pathogen signaling 
via pattern recognition receptors. This would explain the 
more efficient cross-presentation of EV-derived antigens 
compared to soluble antigens [58], as ROS are a major 
factor in upregulating cross-presentation [55, 57, 60, 
61, 83]. However, the effects of EV-containing ROS 
on antigen presentation are difficult to discern from the 
effects of other EV components, such as micro-RNAs.
The molecular mechanisms by which EVs affect 
DC maturation and the role of EV-encapsulated ROS 
in this process are still largely unknown. In murine 
CD11b+ myeloid DC precursors, tumor EVs inhibited 
the differentiation of DCs via enhanced expression 
of interleukin 6 (IL-6) [84]. After EV uptake, CD11c 
expression was significantly lowered and IL-6 expression 
was higher than in the control cultures. Precursor DCs 
were able to differentiate in the CD11c+ phenotype, 
but these DCs were less able to mature as measured by 
analysis of the expression of the co-stimulatory molecules 
CD86 and CD80. The expression of CD86 and CD80 was 
significantly lower and correlated with the concentration 
of EVs added to the culture [84]. When DC precursors 
were isolated from IL-6 knockout mice, DC maturation 
was not inhibited, suggesting that the inhibition is 
mediated by IL-6. The authors observed similar effects 
on differentiation of human CD14+ monocytes into 
monocyte-derived DCs after stimulation with isolated 
EVs from the MDA-MB-231 breast cancer cell line. In 
conclusion, several immunologically relevant effects of 
EVs have been described, many of which are likely to 
depend at least partly on EVs containing ROS. However, 
the effects of other compounds present in EVs cannot be 
excluded and this requires further investigation.
The TME is hypoxic
As mentioned above, a major cause for the generation 
of ROS in the TME is a disturbed metabolism of the cancer 
cells. Since ROS generation consumes molecular oxygen, 
this increases the hypoxic conditions caused by the poor 
vascularization frequently associated with tumors [85]. 
A major signaling component downstream of hypoxia is 
the HIF family of transcription factors, consisting of HIF-
1α, HIF-2α and HIF-1β. At normoxic conditions, the alpha 
subunit is targeted for degradation via hydroxylation by 
prolyl hydroxylase domain enzymes and factor inhibiting 
HIF-1α. Upon hydroxylation, HIF-1α and HIF-2α bind to 
the von Hippel–Lindau tumor-suppressor protein, allowing 
ubiquitination and ultimately proteasomal degradation 
[86–88]. The hydroxylation reaction requires oxygen 
and therefore cannot efficiently occur under hypoxic 
conditions, resulting in the accumulation of the HIF-
1α and/or HIF-2α subunits, allowing them to dimerize 
with HIF-1β and translocate to the nucleus. Here, the 
heterodimer binds to the hypoxia responsive element 
(HRE) in the promotor region of target genes [89–91]. 
Many of the HIF target genes are involved in angiogenesis 
and in erythropoiesis, and HIF also promotes glycolysis 
by upregulating expression of plasma membrane glucose 
transporters and inhibiting pyruvate dehydrogenase 
kinase, which blocks the translocation of pyruvate to the 
tricarboxylic acid cycle [92, 93]. 
Hypoxia alters DC differentiation and 
maturation
The effects of hypoxia on the differentiation and 
maturation of DCs are quite well studied, although there is 
little consensus between studies. For example, expression 
of MHC-II is mostly reported to decrease in hypoxic 
environments [94–99], but the opposite [100] or no effect 
[101, 102] have been reported as well. The same holds 
for DC maturation markers like CD80, CD83 or CD86, 
where several studies found no effects [99, 101, 102], but 
upregulation [100] and downregulation [95–97, 103] were 
reported as well. Hypoxic alteration of MHC-I expression 
is less well studied, however HIF-1α activity is implied in 
upregulating MHC-I expression [104]. These contradicting 
results likely arise from the complex interplay of ROS and 
hypoxia signaling with immune cell activation pathways. 
In particular, hypoxia is capable of altering TLR signaling 
[105] and subsequently leads to altered cytokine secretion 
patterns [95, 100]. Expression of TLR4 [106] and its 
downstream kinase MAP3K8 (also known as Cot or 
TPL-2) are upregulated by hypoxia [90, 107]. This leads 
to an hypoxic potentiation of TLR4-mediated secretion 
of TNF-α in human monocyte-derived DCs [107]. In 
line with this, hypoxia has also been found to increase 
secretion of other pro-inflammatory cytokines such as 
IL-6, IL-8 and IL-1β in primary human macrophages and 
osteoclasts [95, 108–110]. So, while hypoxia itself does 
not cause ROS formation, it can trigger inflammation 
which in turn promotes ROS formation. Since ROS 
formation consumes oxygen, it causes additional hypoxia, 
resulting in a feedback loop.
Hypoxia skews immature DCs towards a highly 
mobile phenotype by upregulating genes involved in cell 
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motility [111]. The chemokine receptors CCR2, CCR3, 
CCR5, CX3CR1, C5R1 and FPR3 are upregulated upon 
hypoxia, while expression of chemokines CCL26, CCL24 
and CCL14 are inhibited by hypoxia [98, 112]. This 
suggests that immature DCs differentiated in a hypoxic 
TME migrate away towards normoxic tissues, potentially 
suppressing anti-tumor immunity. Moreover, a variety 
of tumors secrete elevated levels of prostaglandin E2, 
which is a strong migratory stimulus for immature DCs 
[112]. Prostaglandin E2 is generated by cyclooxygenases, 
many of which are HIF target genes [90, 108]. In contrast, 
mature DCs downregulate expression of CCR7 in hypoxic 
conditions. CCR7 is the chemokine receptor which signals 
DCs to migrate to draining lymph nodes in response to 
lymph node derived chemokines [98]. This observation 
is in line with the poor chemotactic ability of hypoxic 
mature DCs in response to the lymph node chemokine 
MIP-3β. Thus, evidence suggests that the hypoxic TME 
promotes the expulsion of immature DCs from the tumor, 
whereas the migration of mature DCs to the lymph nodes 
is reduced. 
The effects of hypoxia on DC maturation might 
well be transient. Murine DCs cultured under low oxygen 
tensions expressed lower levels of MHC-II, CD80 and 
CD86 compared to DCs under normoxic conditions [96]. 
However, reoxygenation of hypoxia-differentiated DCs 
restored the levels of these maturation markers, suggesting 
that once these DCs migrate towards the lymph nodes they 
can regain full functionality [96]. Finally, hypoxia affects 
antigen uptake as it decreased the phagocytic capacity of 
immature DC compared to DCs cultured under normoxic 
conditions [98]. In conclusion, hypoxia can both increase 
and decrease DC maturation, likely depending on the 
presence of ROS and other inflammatory stimuli in the 
TME. Moreover, hypoxia can promote immune tolerance, 
as it stimulates migration of immature DCs out of the 
TME while restricting migration of mature DCs to prevent 
T cell activation in draining lymph nodes.
Hypoxia skews T helper cell differentiation by DCs
T cell priming is an essential function of DCs and 
this process is affected by the TME as well. Immature 
blood monocyte-derived DCs cultured at hypoxic 
conditions were found to be biased towards a Th2-
stimulatory phenotype by switching to secretion of IL-4 
instead of IFN-γ [98]. These T cells mostly stimulate a 
humoral immune response and suppress DC activation via 
IL-10 secretion. In addition, DCs cultured under hypoxia 
secreted increased amounts of osteopontin, which strongly 
promotes tumor cell migration [98]. However, osteopontin 
might also promote an immune response, as it promotes 
IFN-α production via TLR9 signaling in plasmacytoid 
DCs, which upregulates the expression of MHC-I [113]. 
The TME also affects T cell recruitment to the tumor, as 
long-term hypoxia for multiple days was shown to increase 
the expression cytokines CCL3, CCL5 and CCL20 in 
mature DCs [114]. These cytokines are chemotactic 
for both activated and memory T cells, monocytes and 
immature DCs. Finally HIF-1α activates transcription 
of retinoic acid receptor-related orphan nuclear receptor 
gamma (RORγt) and together these two factors regulate the 
transcription of IL-17 [115]. Therefore, hypoxia increases 
the differentiation of T cells towards regulatory T helper 
17 (Th17) cells via IL-6 in a uniquely TGF-β independent 
fashion [116]. Regulatory Th17 cells are associated with 
host defense and autoimmune inflammatory responses 
[117, 118] and promote tumor growth [115].
DISCUSSION
In this review, we discussed how the hypoxic, 
oxidative environment of the TME influences invading 
immune cells. Figure 2 shows an overview of the major 
effects that have been found so far. The effects of the 
cytokines and chemokines found in the TME have been 
quite extensively studied. In contrast, comparatively little 
is known about the effects on tumor invading immune 
cells of localized ROS and hypoxia that frequently 
hallmark the TME. Both the tumor cells and the immune 
cells produce various forms of ROS, that directly affect 
the cell physiology but can also target neighboring cells, 
either by diffusion of ROS or by ROS encapsulated in 
EVs (Figure 1). ROS generation consumes oxygen and is 
therefore often paired with local hypoxia, whereas hypoxia 
can promote formation of ROS, making it difficult to 
differentiate the effects of ROS and hypoxia from each 
other. As described in this review, the effects of hypoxia on 
DC phenotype and maturation are under debate. However, 
it is becoming increasingly clear that hypoxia stimulates 
migration of immature DCs but prevents migration of 
mature DCs. This might result in the TME becoming an 
immunosuppressive “DC trap”, with limited influx and 
maturation of immature DCs while the egress of activated 
DCs is prevented. However, in contrast to this, hypoxia 
seems to upregulate secretion of various pro-inflammatory 
anti-tumorigenic cytokines. Maybe these contradicting 
effects are the result of ROS signaling. 
A major question is whether tumor cells use 
EV release as a protective mechanism from oxidative 
damage as a result of their high anaerobic metabolic 
activity, or as an active defense mechanism to prevent 
immune responses. However, due to the small size and 
heterogeneity of EVs, it is difficult to study their content. 
In vitro approaches using artificial membranes carrying 
ROS might help to overcome this problem. Another 
problem is that resolving the physiological effects of 
specific sources and types of ROS remains challenging, 
due to their highly transient nature and the lack of specific 
probes that offer adequate spatiotemporal resolution. 
Controlling specific redox signaling and antioxidant 
pathways would be a valid approach to this problem, since 
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these parameters can be modified with genetic techniques. 
In addition, ROS can be induced with organellar precision 
using fusion constructs of proteins with known cellular 
location with photosensitizer proteins like SuperNova 
[119]. Likewise, culture media can be supplemented with 
a wide range of antioxidants or radical-generating systems. 
Another key question is whether ROS can be 
used to treat cancer. A possible avenue would be local 
administration of pro-oxidants in the TME. Tumor cells 
often display a defective Nrf2 pathway, rendering them 
more susceptible to oxidative stress [120], while DC 
maturation can be enhanced by ROS as described above. 
In a xenograft mouse model of chronic lymphocyte 
leukemia, pro-oxidative treatment strongly reduced 
tumor burden [120]. However, since ROS also has 
pro-tumorigenic effects, the opposite approach of 
administrating anti-oxidants is also possible. There 
have been several randomized controlled trials in which 
prophylactic effects of such antioxidant supplementation 
was investigated. However, for incidence of prostate and 
total cancer in men, supplemental vitamin E had no effects 
[121–123] and in one study even significantly increased 
prostate cancer incidence [124].
Since the effects of ROS on cancer and immune 
cells are complex and dependent on the site of ROS 
generation and the interplay with hypoxia and immune 
Figure 2: Combined effects of ROS and hypoxia in the TME. ROS promote DC maturation, antigen cross-presentation, DC 
migration and CD8+ T cell responses needed for anti-tumor immunity. In contrast, hypoxia can both lower or increase DC maturation 
and skews T cell responses towards a tolerogenic Th17 response. Moreover, hypoxia can inhibit ingress of immature DCs into the tumor 
whilst blocking migration of mature DCs from the tumor to draining lymph nodes. Hypoxia does however promote secretion of various 
inflammatory cytokines such as TNF-α.
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signaling, targeting ROS by simply administering pro- 
or antioxidants on might not be sufficient. Targeting 
ROS or antioxidants to a specific cell type may provide 
a more successful strategy to combat cancer. For 
instance, promoting ROS formation in the lumen of endo/
phagosomes of DCs could be a strategy to promote antigen 
cross-presentation [55–57, 60, 61, 63, 125], whereas 
blockage of mitochondrial ROS formation might increase 
T cell activation in the lymph nodes [64]. In the paper 
by Dingjan et al., the photosensitizer protein KillerRed 
[126] was employed to increase endosomal ROS in DCs by 
transfecting a plasmid encoding a KillerRed fusion protein 
targeted to phagosomes. However, transfection of tumor-
associated DCs in vivo is still very challenging. An alternative 
approach would be to target DCs with nanoparticles carrying 
a ROS-inducer [127–129], for example an iron core that 
promotes generation of highly reactive hydroxyl radicals 
through Fenton chemistry [130, 131]. 
In a similar fashion, cancer cells might be 
specifically targeted with antioxidants to block the pro-
tumorigenic effects of ROS. While, as described above, 
systemic antioxidant therapy proved unsuccessful in 
cancer, localized interventions are still worth considering. 
Endosomal NOX2 activity was recently shown to play 
an important role in progression of prostate cancer [132], 
which could be targeted (for instance with antibodies) with 
antioxidant-carrying small particles for exclusive uptake 
via endocytosis by tumor cells [133]. Another interesting 
targeting approach is ROS-responsive nanoparticles 
for targeted delivery of hydrophilic and cationic drugs 
in ROS-producing cells [134]. In this study, Meng et 
al. showed that MnO2-based nanoparticles selectively 
release the HIF-1 inhibitor acriflavine in tumor cells after 
oxidation by H2O2 in vitro and in a mouse model of colon 
cancer. Although the authors did not investigate uptake by 
phagocytic cells, it is likely that this method is also capable 
of releasing compounds in phagosomes. Finally, it might be 
highly beneficial to sequester lipid peroxidation products 
such as MDA and 4-HNE due to their negative impact on 
DC function, as described above. Doing so would protect 
DCs against these effects without interfering with ROS-
induced cross-presentation and DC maturation. Several 
potential compounds have been identified recently that 
warrant further investigation, of which histidine-containing 
dipeptides are currently the most promising [135–137].
Given that cancer cells use hypoxia and ROS 
to reprogram immune and stromal cells in the TME 
to prevent an immune response and augment tumor 
progression, while at the same time the immune system 
uses ROS to signal inflammation and combat infection, 
ROS have huge therapeutic potential for combating 
cancer. Given this duality, the timing and localization of 
pro- or antioxidant interventions is likely highly critical. 
Understanding the intricate pathways of the production, 
signalling and effector responses of hypoxia and ROS is 
essential for designing such therapies.
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